STOCK TITAN

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Alector, Inc. (Nasdaq: ALEC) will host a conference call on February 27, 2024, to discuss fourth-quarter results and provide a full-year business update. The event will be webcast live on their website.
Positive
  • None.
Negative
  • None.

Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Tuesday, February 27, 2024, at 4:30 p.m. ET to discuss results for the fourth quarter ended December 31, 2023, and provide a full-year business update. A press release detailing fourth quarter results will be issued prior to the call.

The event will be webcast live under the investor relations section of Alector’s website at https://investors.alector.com/events-and-presentations/events and following the event a replay will be archived there for 30 days. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California.

Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com

1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com

Argot Partners (investors)
Laura Perry
212.600.1902
alector@argotpartners.com


Alector, Inc. is hosting a conference call on February 27, 2024, at 4:30 p.m. ET.

The ticker symbol for Alector, Inc. is ALEC.

Interested parties can find the webcast of the event on Alector's website under the investor relations section.

The replay of the webcast will be archived on Alector's website for 30 days following the event.

Phone participants need to register using an online form to receive dial-in details and a personal PIN number via email.
Alector, Inc.

NASDAQ:ALEC

ALEC Rankings

ALEC Latest News

ALEC Stock Data

489.63M
75.76M
9.93%
79.61%
6.76%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About ALEC

we are a biotech company based in san francisco dedicated to the discovery and development of novel therapies harnessing the power of immune system to treat neurodegenerative diseases such as alzheimer's disease.